Sep 29, 2019 · In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E–mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens.

Sep 23, 2024 · A phase Ib/II trial of combined BRAF and EGFR inhibition in BRAF V600E positive metastatic colorectal cancer and other cancers: the EVICT (Erlotinib and Vemurafenib In Combination Trial)...

BRAF V600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line.

4 days ago · Background: Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study (NCT02928224). Historically, first-line (1L) treatment of BRAF V600E-mutant mCRC with chemotherapy (chemo) regimens has had limited efficacy.BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating 1L ...

May 3, 2022 · Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint inhibitors. Worldwide, colorectal cancer (CRC) is the third most common cancer and the second highest cause of cancer-related mortality.

5 days ago · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study.

Sep 1, 2024 · BRAFV600E -mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates.

Apr 1, 2023 · Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in approximately 8–12% of patients and is characterised by an aggressive clinical course and poor prognosis.

Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAF V600E mutation occurs in approximately 8-12% of patients and is characterised by an aggressive clinical course and poor prognosis.